
Abiologics launches with a new class of supranatural medicines
Abiologics, a Flagship Pioneering company, has launched to develop a new class of supranatural and programmable medicines called Synteins. Synteins are computationally-generated and synthesised with novel building blocks, potentially providing treatments across a wide range of diseases. Flagship has initially committed $50 million to advance the company’s platform and develop… Read More













